Previous studies have demonstrated that EP receptor subtypes (EP1, EP2, EP3, and EP4) contribute to lung-cancer progression (59–66), suggesting the potential therapeutic advantage of targeting PGE2 synthesis in the lungs rather than focusing on individual receptors. Here, PTGER3 is linked to lung carcinoma.